论文部分内容阅读
目的:研究舒必利、奥美拉唑联合铝碳酸镁在反流性胃炎当中的疗效,并分析该治疗方式对患者血清VIP、IL-6水平的影响。方法:以我院2015年2月至2017年2月期间收治的200例反流性胃炎患者为研究对象。随机分成观察组与对照组,均给予常规基础治疗。观察组给予舒必利、奥美拉唑联合铝碳酸镁治疗;对照组给予舒必利、奥美拉唑治疗。对比两组患者的症状积分与血清VIP、IL-6水平情况。结果:治疗后2组患者的症状积分与血清VIP、IL-6水平均有显著下降,与治疗前相比差异具有统计学意义(p<0.05),且治疗后观察组患者的症状积分与血清VIP、IL-6水平下降情况比对照组显著,差异具有统计学意义(p<0.05)。结论:舒必利、奥美拉唑联合铝碳酸镁有助于提高反流性胃炎的疗效,显著降低患者的症状积分和血清VIP、IL-6水平,值得临床推广。
Objective: To study the curative effect of sulpiride and omeprazole combined with hydrotalcite in patients with reflux gastritis and to analyze the effect of this treatment on serum VIP and IL-6 levels. Methods: 200 cases of patients with reflux gastritis admitted to our hospital from February 2015 to February 2017 were selected as the study subjects. Randomly divided into observation group and control group, were given routine basic treatment. The observation group was treated with sulpiride and omeprazole in combination with magnesium aluminum carbonate. The control group was treated with sulpiride and omeprazole. Symptom scores and serum levels of VIP and IL-6 were compared between the two groups. Results: After treatment, the scores of symptoms and serum VIP and IL-6 in two groups were significantly decreased (P <0.05), and the scores of symptom scores in the observation group and serum VIP, IL-6 levels decreased significantly than the control group, the difference was statistically significant (p <0.05). CONCLUSIONS: Sulpiride and omeprazole combined with magnesium aluminum carbonate help to improve the curative effect of reflux gastritis and significantly reduce the patient’s symptom scores and serum levels of VIP and IL-6, which is worthy of clinical promotion.